ATE234282T1 - Polymorphe verbindungen - Google Patents

Polymorphe verbindungen

Info

Publication number
ATE234282T1
ATE234282T1 AT97929654T AT97929654T ATE234282T1 AT E234282 T1 ATE234282 T1 AT E234282T1 AT 97929654 T AT97929654 T AT 97929654T AT 97929654 T AT97929654 T AT 97929654T AT E234282 T1 ATE234282 T1 AT E234282T1
Authority
AT
Austria
Prior art keywords
pct
fluvastatin sodium
fluvastatin
sodium form
sec
Prior art date
Application number
AT97929654T
Other languages
German (de)
English (en)
Inventor
Karol Horvath
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9602477A external-priority patent/SE9602477D0/xx
Priority claimed from SE9700751A external-priority patent/SE9700751D0/xx
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE234282T1 publication Critical patent/ATE234282T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
AT97929654T 1996-06-24 1997-06-18 Polymorphe verbindungen ATE234282T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9602477A SE9602477D0 (sv) 1996-06-24 1996-06-24 Polymorphic compounds
SE9700751A SE9700751D0 (sv) 1997-03-03 1997-03-03 Polymorphic compounds
PCT/SE1997/001097 WO1997049681A1 (en) 1996-06-24 1997-06-18 Polymorphic compounds

Publications (1)

Publication Number Publication Date
ATE234282T1 true ATE234282T1 (de) 2003-03-15

Family

ID=26662685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929654T ATE234282T1 (de) 1996-06-24 1997-06-18 Polymorphe verbindungen

Country Status (11)

Country Link
US (1) US6124340A (enExample)
EP (1) EP0907639B1 (enExample)
JP (2) JP4282092B2 (enExample)
AT (1) ATE234282T1 (enExample)
AU (1) AU3366297A (enExample)
CY (1) CY2461B1 (enExample)
DE (1) DE69719755T2 (enExample)
DK (1) DK0907639T3 (enExample)
ES (1) ES2194202T3 (enExample)
PT (1) PT907639E (enExample)
WO (1) WO1997049681A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902202D0 (sv) 1999-06-10 1999-06-10 Astra Ab Production of aggregates
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
JP2004513112A (ja) * 2000-10-31 2004-04-30 チバ　スペシャルティ　ケミカルズ　ホールディング　インコーポレーテッド フルバスタチンナトリウムの結晶形
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
ES2304140T3 (es) * 2001-08-03 2008-09-16 Ciba Holding Inc. Formas cristalinas de sodio de fluvastatina.
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE10316087A1 (de) * 2003-04-08 2004-11-11 Ratiopharm Gmbh Polymorphstabilisierung von Fluvastatin-Natrium in Pharmazeutischen Formulierungen
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
EP1790634A3 (en) * 2003-06-18 2007-06-13 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal form and processes for preparing it
US7368581B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006008656A2 (en) * 2004-07-21 2006-01-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
WO2006038219A1 (en) * 2004-10-05 2006-04-13 Biocon Limited Process for the preparation of amorphous fluvastatin sodium
WO2006085338A2 (en) * 2005-02-11 2006-08-17 Jubilant Organosys Limited Novel polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
KR20080005230A (ko) * 2006-02-27 2008-01-10 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 신규 형태 및 이의 제조 방법
ATE431818T1 (de) 2006-04-20 2009-06-15 Italiana Sint Spa Verfahren zur herstellung von fluvastatin-natrium
CN101250153B (zh) * 2008-02-26 2013-09-18 深圳信立泰药业股份有限公司 一种制备氟伐他汀钠晶型的工艺
PT2419407E (pt) * 2009-04-15 2013-01-28 Pharmathen Sa Processo melhorado para a preparação de fluvastatina e dos seus sais
CN114280181B (zh) * 2021-12-23 2024-06-18 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Also Published As

Publication number Publication date
CY2461B1 (en) 2005-06-03
DK0907639T3 (da) 2003-06-23
JP4282092B2 (ja) 2009-06-17
PT907639E (pt) 2003-06-30
JP2009149654A (ja) 2009-07-09
DE69719755D1 (de) 2003-04-17
WO1997049681A1 (en) 1997-12-31
US6124340A (en) 2000-09-26
EP0907639B1 (en) 2003-03-12
DE69719755T2 (de) 2003-11-20
EP0907639A1 (en) 1999-04-14
AU3366297A (en) 1998-01-14
JP2000512992A (ja) 2000-10-03
ES2194202T3 (es) 2003-11-16

Similar Documents

Publication Publication Date Title
DE69719755D1 (de) Polymorphe verbindungen
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
IL116385A0 (en) Sulphonamides their manufacture and pharmaceutical compositions containing them
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
HU9601218D0 (en) Distamycin a analogue utilizable as antitumoral and antiviral medicines
DE60224189D1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
PL376822A1 (pl) Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
DE69830504D1 (de) Antithrombotische mitteln
DE60330485D1 (de) Zur behandlung von diabetes
BR9611175B1 (pt) compostos e composiÇÕes farmacÊuticas.
HUT77925A (hu) Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra
MXPA04000577A (es) Derivados de dolastatina 10.
AU2672995A (en) {a}-annelated pyrrole derivatives and pharmaceutical uses thereof
SE9404080D0 (sv) Förfarande för framställning av en optiskt ren enantiomer av formoterol
DK1556362T3 (da) Heterocykliske beta-aminodipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
MX9706647A (es) Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
CY2225B1 (en) Organic compounds
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
DK0775113T3 (da) N-substituerede azabicycloheptan-derivater som neuroleptika osv.
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
EP1027051A4 (en) ANTITHROMBOTIC AGENTS
ES2140683T3 (es) Procedimiento para preparar compuestos de benzopirano.
ES2123796T3 (es) Derivados de acidos fosfono-succinicos y su utilizacion como medicamentos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0907639

Country of ref document: EP